SCHEMBL4667595

SCHEMBL4667595

FC(F)(F)c1ccc(C(OCCOC(c2ccccc2)c2ccc(C(F)(F)F)cc2)c2ccccc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.52
SCN1A P35498 3/20 0.49
SCN2A Q99250 3/20 0.49
SCN3A Q9NY46 3/20 0.49
SLC6A2 P23975 3/20 0.49
SLC6A4 P31645 3/20 0.49
SLC6A3 Q01959 3/20 0.49
LMNA P02545 2/20 0.49
TSHR P16473 2/20 0.49
KCNH2 Q12809 2/20 0.49
ACP3 P15309 1/20 0.49
CYP1A2 P05177 1/20 0.49
CHRM2 P08172 1/20 0.49
CHRM4 P08173 1/20 0.49
CHRM5 P08912 1/20 0.49
ADRA2A P08913 1/20 0.49
CYP2D6 P10635 1/20 0.49
CHRM1 P11229 1/20 0.49
ADRA2B P18089 1/20 0.49
CHRM3 P20309 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4667558 0.90 FFAR1 (0.48) FFAR1SCN1ASCN2ASCN3ASLC6A2
SCHEMBL5160316 0.90 SLC6A2 (0.52) FFAR1SLC6A2SLC6A4SLC6A3KCNH2
Formamide SCHEMBL5161701 0.85 SLC6A2 (0.48) FFAR1SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL11054725 0.82 ACP3 (0.53) SLC6A2SLC6A4SLC6A3LMNATSHR
SCHEMBL4667564 0.82 SCN1A (0.65) SCN1ASCN2ASCN3ASLC6A2SLC6A4
SCHEMBL5163408 0.82 ACP3 (0.43) FFAR1SLC6A2SLC6A4SLC6A3TSHR
SCHEMBL4667569 0.79 GAA (0.46) FFAR1MEN1CYP3A4CYP2C9ALOX15
SCHEMBL4667575 0.79 CYP2D6 (0.58) SLC6A2SLC6A4SLC6A3TSHRKCNH2
SCHEMBL11813722 0.76 SCN1A (0.46) SCN1ASCN2ASCN3ASLC6A2SLC6A4
Hydrochloric Acid SCHEMBL5269207 0.76 FFAR1 (0.44) FFAR1IDO1TDO2MEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1930308-A1 Pharmaceutical agents for the treatment of cerebral amyloidosis NYMOX CORPORATION (CA) 2008-06-11 EP disclosed
EP-0983222-B1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 2007-11-28 EP disclosed
US-6518314-B1 For treating cerebral amyloidosis; compounds that impede the transformation of dense microspheres (DMS) into amyloid NYMOX CORPORATION (CA) 2003-02-11 US disclosed
US-6130221-A ALZHEIMERS NYMOX CORPORATION (CA) 2000-10-10 US disclosed
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed